

**REMARKS**

This paper is being filed in response to the Notice to Comply with Sequence Requirements dated March 1, 2002. Applicants request a two-month extension of time and enclose the fee required under 37 C.F.R. §1.17(a)(2). Applicants respectfully request consideration of the above-identified application in light of the amendments and remarks presented in the instant Response.

Rewritten tables appear in the preceding "IN THE SPECIFICATION" section. Attached hereto is a marked-up version of the changes made by the instant amendment captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE" and is included pursuant to 37 C.F.R. §1.121(c)(ii).

Applicants submit herewith a Sequence Listing in paper and computer readable form. I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e), are the same. I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

Support for the sequences listed in the Sequence Listing may be found in the specification as filed, *inter alia*, at Table 1 (SEQ ID NOS:1-19) and Table 2 (SEQ ID NOS:20-29).

Applicants do not believe any fee beyond the extension of time fee is required for this filing. However, any required fees not otherwise enclosed herewith may be charged to Deposit Account No. 02-4377. Two copies of this page are enclosed.

July 1, 2002

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Lisa B. Kole", written over a horizontal line.

Lisa B. Kole

PTO Reg. No. 35,225

Attorney for Applicants  
BAKER BOTTS, L.L.P.  
30 Rockefeller Plaza  
New York, NY 10112  
(212) 408-2628

Enclosures

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

In this section, added text is highlighted, e.g. **added text**. No text has been deleted.

**IN THE SPECIFICATION**

Table 1 has been **amended** as follows:

Table 1. Sequence of gene specific primers used in the C-ORF cloning technology.

Primer	Gene	SEQ ID NO	Sequence
AP-1	D-SLAP	1	5' TTCTGGTCGACTAGTGTTTAAACTCGAGAC 3'
AP-2	D-SLAP	2	5' CACGATCAGTCGACGAAGTCGACACTCGAG 3'
M5R1	<i>mda-5</i>	3	5' TTTTTTTTTTTTCAGAGTAAAAACAATC 3'
M5R2	<i>mda-5</i>	4	5' TGTGCACCATCATTGTTCCCCAAGCC 3'
M5R3	<i>mda-5</i>	5	5' AATCTGACATTGGACTCATTTGAC 3'
M5R4	<i>mda-5</i>	6	5' GTTTGAATCCTTGTCATTATTTCTAG 3'
M5S1	<i>mda-5</i>	7	5' GCCTGAGAGCCCTGTGGACAACCTCG 3'
56R1	ISG-56	8	5' GTGGCTGATATCTGGGTGCCTAAGG 3'
56R2	ISG-56	9	5' CCTAAGGACCTTGTCTCACAGAGTTC 3'
56S1	ISG-56	10	5' CCAGATCTCAGAGGAGCCTGGCTAAGC 3'
M9R1	<i>mda-9</i>	11	5' AATCAGGATAAAGTGCAACTATC 3'
M9R2	<i>mda-9</i>	12	5' ATCCCAAAGTAGCTAGGTACATAATC 3'
M9S1	<i>mda-9</i>	13	5' CCTCAGAAGTCCGTGCCAGTGACCGG 3'
FnR1	fibronectin	14	5' TTTTTTTTTTTTGTGGAATGTAAATC 3'
FnR2	fibronectin	15	5' AGATGGATCTTGGCAGAGAGACATGC 3'
PCTAR1	PCTA-1	16	5' GAAGAAGTAGAACATCAGTGCC 3'
PCTAR2	PCTA-1	17	5' TCTTCTGTACAGCAGTATCTTACAT 3'
PCTAR3	PCTA-1	18	5' TTTTTTTTTTTTTTTTGTGTTGCATGCGG 3'
PCTAR4	PCTA-1	19	5' TTACAAACAGCTCCCAAATGGTGAAACT 3'

Table 2 has been **amended** as follows:

Table 2. Sequence of the 5' end of the C-ORF products.

Name	SEQ ID NO	5'	sequence	G/C score	% G/C
<i>mda</i> -20	20	5'	GCGCGCCGGC CT 3'	11/12	91.7
ISG-56	21	5'	TGCAGAACGG CT 3'	7/12	58.3
<i>mda</i> -9	22	5'	GGCGGCGGCG GC 3'	12/12	100.0
PCTA-1A	23	5'	TGGAGGCCTG GA 3'	8/12	66.7
PCTA-1B	24	5'	GCCAGTGCCT CA 3'	8/12	66.7
PCTA-1C	25	5'	CGATGTGGCC TT 3'	7/12	58.3
OLD-35	26	5'	CGGAGGACCA AT 3'	7/12	58.3
PSGen 12	27	5'	GCGGTGGTGA CG 3'	9/12	75.0
PSGen 28	28	5'	GTGTGGTGTG TC 3'	7/12	58.3
PSGen 42	29	5'	GGCGTTGCGA CG 3'	9/12	75.0
G/C/ score	--		8994867986 74	85/120	70.8